Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

RZ Orlowski; A Nagler; Pieter Sonneveld; J Blade; R Hajek; A Spencer; JF San miguel; T Robak; A Dmoszynska; N Horvath; I Spicka; HJ Sutherland; AN Suvorov; SH Zhuang; T Parekh; L Xiu; Z Yuan; W Rackoff; JL Harousseau

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

RZ Orlowski, A Nagler, Pieter Sonneveld, J Blade, R Hajek, A Spencer, JF San miguel, T Robak, A Dmoszynska, N Horvath, I Spicka, HJ Sutherland, AN Suvorov, SH Zhuang, T Parekh, L Xiu, Z Yuan, W Rackoff, JL Harousseau

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

567 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	3892-3901
Number of pages	10
Journal	Journal of Clinical Oncology
Volume	25
Publication status	Published - 2007

Cite this

Orlowski, RZ., Nagler, A., Sonneveld, P., Blade, J., Hajek, R., Spencer, A., San miguel, JF., Robak, T., Dmoszynska, A., Horvath, N., Spicka, I., Sutherland, HJ., Suvorov, AN., Zhuang, SH., Parekh, T., Xiu, L., Yuan, Z., Rackoff, W., & Harousseau, JL. (2007). Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. Journal of Clinical Oncology, 25, 3892-3901.

Orlowski, RZ ; Nagler, A ; Sonneveld, Pieter ; Blade, J ; Hajek, R ; Spencer, A ; San miguel, JF ; Robak, T ; Dmoszynska, A ; Horvath, N ; Spicka, I ; Sutherland, HJ ; Suvorov, AN ; Zhuang, SH ; Parekh, T ; Xiu, L ; Yuan, Z ; Rackoff, W ; Harousseau, JL. / Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. In: Journal of Clinical Oncology. 2007 ; Vol. 25. pp. 3892-3901.

@article{840140651fd54436be544c011e868d2d,

title = "Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression",

author = "RZ Orlowski and A Nagler and Pieter Sonneveld and J Blade and R Hajek and A Spencer and {San miguel}, JF and T Robak and A Dmoszynska and N Horvath and I Spicka and HJ Sutherland and AN Suvorov and SH Zhuang and T Parekh and L Xiu and Z Yuan and W Rackoff and JL Harousseau",

year = "2007",

language = "Undefined/Unknown",

volume = "25",

pages = "3892--3901",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

}

Orlowski, RZ, Nagler, A, Sonneveld, P, Blade, J, Hajek, R, Spencer, A, San miguel, JF, Robak, T, Dmoszynska, A, Horvath, N, Spicka, I, Sutherland, HJ, Suvorov, AN, Zhuang, SH, Parekh, T, Xiu, L, Yuan, Z, Rackoff, W & Harousseau, JL 2007, 'Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression', Journal of Clinical Oncology, vol. 25, pp. 3892-3901.

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. / Orlowski, RZ; Nagler, A; Sonneveld, Pieter; Blade, J; Hajek, R; Spencer, A; San miguel, JF; Robak, T; Dmoszynska, A; Horvath, N; Spicka, I; Sutherland, HJ; Suvorov, AN; Zhuang, SH; Parekh, T; Xiu, L; Yuan, Z; Rackoff, W; Harousseau, JL.

In: Journal of Clinical Oncology, Vol. 25, 2007, p. 3892-3901.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

AU - Orlowski, RZ

AU - Nagler, A

AU - Sonneveld, Pieter

AU - Blade, J

AU - Hajek, R

AU - Spencer, A

AU - San miguel, JF

AU - Robak, T

AU - Dmoszynska, A

AU - Horvath, N

AU - Spicka, I

AU - Sutherland, HJ

AU - Suvorov, AN

AU - Zhuang, SH

AU - Parekh, T

AU - Xiu, L

AU - Yuan, Z

AU - Rackoff, W

AU - Harousseau, JL

PY - 2007

Y1 - 2007

M3 - Article

VL - 25

SP - 3892

EP - 3901

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

ER -